The Usefulness of Definitive Screening Design for a Quality by Design Approach as Demonstrated by a Pharmaceutical Study of Orally Disintegrating Tablet.

central composite design definitive screening design design of experiment orally disintegrating tablet quality by design two-factor orthogonal array design

Journal

Chemical & pharmaceutical bulletin
ISSN: 1347-5223
Titre abrégé: Chem Pharm Bull (Tokyo)
Pays: Japan
ID NLM: 0377775

Informations de publication

Date de publication:
2019
Historique:
entrez: 5 10 2019
pubmed: 5 10 2019
medline: 12 11 2019
Statut: ppublish

Résumé

Definitive screening design (DSD) is a new class of small three-level experimental design that is attracting much attention as a technical tool of a quality by design (QbD) approach. The purpose of this study is to examine the usefulness of DSD for QbD through a pharmaceutical study on the preparation of ethenzamide-containing orally disintegrating tablet. Model tablets were prepared by directly compressing the mixture of the active pharmaceutical ingredient (API) and excipients. The five evaluated factors assigned to DSD were: the contents of API (X1) and lubricant (X2), and the compression force (X3) of the tableting process, the mixing time (X4), and the filling ratio of powder in the V-type mixer (X5). After tablet preparation, hardness and disintegration time were measured. The same experiments were performed by using the conventional design of experiments [i.e., L8 and L16 orthogonal array designs and central composite design (CCD)]. Results showed that DSD successfully clarified how various factors contribute to tablet properties. Moreover, the analysis result from DSD agreed well with those from the L8 and L16 experiments. In additional experiments, response surfaces for tablet properties were created by DSD. Compared with the response surfaces created by CCD, DSD could produce reliable response surfaces for its smaller number of experiments. We conclude that DSD is a powerful tool for implementing pharmaceutical studies including the QbD approach.

Identifiants

pubmed: 31582634
doi: 10.1248/cpb.c19-00553
doi:

Substances chimiques

Pharmaceutical Preparations 0
Tablets 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1144-1151

Auteurs

Keisuke Takagaki (K)

Department of Pharmaceutics, Hoshi University.

Terushi Ito (T)

Laboratory of Pharmaceutical Technology, Graduate School of Medical and Pharmaceutical Science, University of Toyama.

Hiroaki Arai (H)

Department of Pharmaceutics, Hoshi University.

Yasuko Obata (Y)

Department of Pharmaceutics, Hoshi University.

Kozo Takayama (K)

Faculty of Pharmacy and Pharmaceutical Sciences, Josai University.

Yoshinori Onuki (Y)

Laboratory of Pharmaceutical Technology, Graduate School of Medical and Pharmaceutical Science, University of Toyama.

Articles similaires

Humans Pharmaceutical Preparations Drug Utilization Prescription Drugs
Alzheimer Disease Humans Regression Analysis Quantitative Structure-Activity Relationship Drug Design
Humans Chondrocytes Osteoarthritis Matrix Metalloproteinase 13 Drug Discovery

Characterization of 3D printed composite for final dental restorations.

Lucas Eigi Borges Tanaka, Camila da Silva Rodrigues, Manassés Tércio Vieira Grangeiro et al.
1.00
Composite Resins Materials Testing Printing, Three-Dimensional Surface Properties Flexural Strength

Classifications MeSH